The board of directors of DaVita (DVA) increased the authorization under the company’s existing share repurchase program by $2B in additional repurchasing authority, the company disclosed in a regulatory filing. The amount of shares of common stock authorized to be repurchased under the new authorization does not include the amount remaining under the company’s existing share repurchase program authorized on September 5, 2024, it noted.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVA:
- Berkshire trimmed Apple, DaVita, Charter, Bank of America stakes in Q2
- Berkshire Hathaway takes new stake in UnitedHealth, trims Apple stake
- DaVita price target lowered to $148 from $164 at Truist
- DaVita price target lowered to $154 from $157 at TD Cowen
- DaVita price target lowered to $160 from $169 at Barclays